&nbsp; <P><STRONG>The company ElsaLys Biotech, from Lyon, specializes in the development of therapeutic antibodies and has just raised &#8364;2.1 million in funding.</STRONG> <A title="" href="https://www.aderly.com/lyon-economic-news/news-TRANSGENE,n,2288,EN.jsp" target=_blank>Transgene, a biopharmaceutical company </A>which develops new generation immunotherapy products targeting cancers and infectious diseases, and the Sofimac Partners investment fund, announced their contribution to a first round of financing with the ElsaLys Biotech managers.</P> <P align=justify><BR>Created and managed by former Transgene executives, the ElsaLys Biotech start-up is a company at the interface of academic research and the pharmaceuticals industry. <STRONG>Their goal is to convert promising therapeutic targets into drug candidates</STRONG>. The company already has 4 new R&amp;D projects with large academic laboratories and prestigious partners. ElsaLys Biotech is also supported by the Lyonbiop&#244;le global competitiveness cluster.</P> <P align=justify>&nbsp;</P> <P align=justify>ElsaLys Biotech&#8217;s objective is to &#8220;<EM>bring a first antibody candidate to clinical development stage in three years</EM>&#8221;. In pursuing this goal,&nbsp; Dr Bonnefoy, co-founder and CEO of ElsaLys Biotech, stressed the fact that they will benefit from the &#8220;<EM>Transgene <STRONG>team&#8217;s know-how in immunotherapy,&nbsp; solid experience in the therapeutic antibody field, the first promising therapeutic targets, and ad hoc funding from two strong shareholders who combine technological expertise and financial resources</STRONG></EM>&#8221;.<BR><BR></P>